Drug Profile

METI 101

Alternative Names: METI-101

Latest Information Update: 09 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MetiMedi Pharmaceuticals
Class Anti-inflammatories; Antineoplastics; Hepatoprotectants
Mechanism of Action Metabolism modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Cancer
No development reported Non-alcoholic steatohepatitis

Most Recent Events

07 Oct 2025 METI 101 is still in preclinical development in Cancer in South Korea (MetiMedi Pharmaceuticals pipeline, October 2025)
28 Feb 2025 No recent reports of development identified for preclinical development in Cancer in South Korea
28 Sep 2024 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in South Korea

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com